The global spatial genomics and transcriptomics market was valued at USD 232.5 million in 2022 and is expected to expand significantly, reaching USD 574.3 million by 2030. This growth represents a compound annual growth rate of 12.2% during the period from 2023 to 2030. Increasing adoption of spatial genomics and transcriptomics in drug discovery and development is a primary factor driving market expansion.

Over recent years, the application scope of spatial genomics and transcriptomics has progressed beyond academic research and is now strongly focused on pharmaceutical and clinical use cases. The technology is increasingly utilized in drug discovery and development, particularly for complex diseases such as cancer and neurodegenerative disorders. The growing potential of spatial genomic analysis as a cancer detection and diagnostic tool, combined with advancements such as fourth-generation sequencing technologies, is expected to further accelerate market growth.

Key Market Trends & Insights

• North America dominated the market, accounting for 44.47% of the revenue share in 2022.
• The Asia Pacific region is anticipated to be the fastest-growing regional market over the forecast period.
• By technology, the spatial transcriptomics segment held the largest revenue share of 79.0% in 2022.
• By product, the consumables segment accounted for the highest revenue share of 52.6% in 2022.

Market Size and CAGR

• 2022 Market Size: USD 232.5 million
• 2030 Projected Market Size: USD 574.3 million
• CAGR (2023–2030): 12.2%
• Largest Regional Market (2022): North America

Research findings continue to reinforce the clinical value of spatial transcriptomics. A Frontiers Journal paper published in October 2022 highlighted its advantages in identifying and understanding complex spatial structures, including tumor interfaces and tertiary lymphoid structures. The study concluded that spatial transcriptomics has strong potential to enhance pathology diagnostics and enable the discovery of novel cancer prognostic biomarkers. These demonstrated benefits are anticipated to support broader adoption across oncology applications.

Additional factors supporting market growth include the rising demand for personalized medicine, increasing focus on novel biomarker identification, and higher investments in research and development. The growing prevalence of chronic diseases, particularly cancer, has increased diagnostic volumes and the need for advanced molecular diagnostic solutions. According to the National Center for Health Statistics, the U.S. recorded 1,918,030 new cancer cases and 609,360 cancer-related deaths in 2022, underscoring the need for improved diagnostic and therapeutic approaches.

The market is also benefiting from continuous product innovation and strategic investments by key players. In June 2022, during the AGBT general conference in Orlando, 10x Genomics introduced multiple product enhancements across its Chromium, Visium, and Xenium platforms. Similarly, in February 2022, Fulgent Genetics invested in Spatial Genomics Inc. to support the development of seqFISH technology and a multi-omics platform aimed at expanding genetic testing capabilities.

Despite strong growth drivers, certain challenges persist. High equipment costs and a shortage of skilled professionals trained in spatial genomics and transcriptomics technologies are limiting adoption rates, particularly in cost-sensitive markets and emerging regions.

Order a free sample PDF of the Spatial Genomics & Transcriptomics Market Intelligence Study, published by Grand View Research.

Competitive Landscape

The spatial genomics and transcriptomics market is highly competitive, with major players focusing on product launches, partnerships, and collaborative R&D initiatives to strengthen their market presence. In April 2023, Bio-Techne and Lunaphore announced a collaboration to develop the world’s first automated spatial omics multiworkflow system with flexible panel design. Additionally, in February 2023, Curio Bioscience launched Curio Seeker, a high-resolution whole-transcriptome spatial mapping kit, further intensifying market competition.

Key Market Players Include:

• Natera Inc.
• 10x Genomics
• Dovetail Genomics
• Illumina, Inc.
• S2 Genomics, Inc.
• NanoString Technologies, Inc.
• Seven Bridges Genomics
• Horizon Discovery Group plc
• Bio-Techne

Conclusion

The global spatial genomics and transcriptomics market is positioned for robust growth through 2030, supported by expanding applications in drug discovery, cancer research, and precision medicine. Continuous technological advancements, rising R&D investments, and growing clinical validation are expected to sustain market momentum. While high costs and skill shortages remain key challenges, ongoing innovation and strategic collaborations are likely to improve accessibility and adoption, reinforcing the long-term growth outlook for the market.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.